<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139561">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916382</url>
  </required_header>
  <id_info>
    <org_study_id>SONIA 2</org_study_id>
    <nct_id>NCT01916382</nct_id>
  </id_info>
  <brief_title>Suitability of Nitisinone in Alkaptonuria 2</brief_title>
  <acronym>SONIA 2</acronym>
  <official_title>An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 Month Treatment Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proposal to develop the orphan designated drug, nitisinone, for the treatment of a
      rare Mendelian disease, Alkaptonuria (AKU). Thanks to our existing successful fundamental
      and clinical research (cell models, animal models, natural history studies), we are now
      ready for this final stage of clinical development of nitisinone for AKU:  a phase 3
      clinical trial to prove efficacy. The results of DevelopAKUre will allow us to make the case
      to the European Medicines Agency for marketing authorisation of nitisinone for AKU, thereby
      contributing to the goal of the International Rare Diseases Research Consortium of
      developing 200 new therapies by 2020.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24 houre Urine Homogentisic acid</measure>
    <time_frame>year 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Alkaptonuria</condition>
  <arm_group>
    <arm_group_label>Nitisinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Homogentisic acid lowering drug intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>comparrator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>drug</description>
    <arm_group_label>Nitisinone</arm_group_label>
    <other_name>Orfadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient must fulfil the following criteria in order to be included in the study:

        1. Diagnosis of AKU Any Clinical manifestations of AKU, such as clinical ochronosis or
        chronic back/joint pain.

        3. Age â‰¥25 years. 4. Willing and able to visit the investigational site for study visits.
        5. Signed written informed consent given.

        -

        Exclusion Criteria:

        The presence of any of the following will exclude a patient from inclusion in the study:

          1. Currently pregnant or lactating.

          2. Female patient of child-bearing potential not using a reliable method of
             contraception.

          3. Known allergy to nitisinone or any of the constituents of the investigational
             product.

          4. Current malignancy.

          5. Uncontrolled hypertension (blood pressure greater than 180 mmHg systolic or greater
             than 95 mmHg diastolic).

          6. Unstable cardiovascular disease.

          7. Serum potassium &lt; 3.0 mmol/L.

          8. eGFR &lt; 60 mL/min .

          9. ALT &gt; 1.5 x upper limit of normal.

         10. Haemoglobin &lt; 10.0 g/dL.

         11. Platelets &lt; 100 x 109/L.

         12. Total white blood count &lt; 3.0 x 109/L or neutrophil count &lt; 1.5 x 109/L.

         13. History of alcohol or drug abuse.

         14. Participation in another clinical study within 3 months of randomization.

         15. Treatment with nitisinone within 60 days of randomization.

         16. Psychiatric or somatic illness that interferes with compliance or communication with
             health care personnel.

         17. Foreseeable inability to cooperate with given instructions or study procedures.

         18. Any other medical condition which in the opinion of the investigator makes the
             patient unsuitable for inclusion.

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L Ranganath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Liverpool &amp; Broadgreen University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helen Bygott</last_name>
      <phone>0151 706 4197</phone>
      <email>helen.bygott@rlbuht.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Professor Lakshminarayan Ranganath</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alkaptonuria, nitisinone,Ochronosis, Homogentisic acid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alkaptonuria</mesh_term>
    <mesh_term>Ochronosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
